Dr. Martens Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined 1.4% but profit before tax rose 61% as the business prioritized full-price sales and reduced markdowns, especially in the US and APAC. Net debt fell, margins improved, and new retail concepts and markets were launched, with a focus on further growth in FY 2027.
-
Q3 saw accelerated growth in the Americas, strong wholesale gains across all regions, and robust performance in shoes, while EMEA retail lagged due to a tough consumer environment. Inventory and cost controls remain strong, and early U.S. price increases show no negative impact.
-
Revenue and profit improved year-on-year, driven by higher full-price sales, cost control, and growth in the Americas and APAC. Strategic execution is on track, with new product launches, expanded partnerships, and technology investments supporting future growth.
Fiscal Year 2025
-
A new consumer-first strategy aims to drive sustainable, profitable growth by broadening product offerings, optimizing market-specific distribution, and leveraging brand strengths. Financial discipline, operational improvements, and technology investments support mid to high teens EBIT margin targets over the medium term.
-
Stabilization achieved in FY25 with Americas DTC growth, cost reductions, and significant inventory and debt improvements. Revenue and EBIT declined YoY but met guidance, while strong cash flow and disciplined cost management set up for future growth.
-
Q3 results met expectations with USA DTC up 4% and APAC strong, while EMEA was flat due to less discounting. Guidance is unchanged, inventory is down, and cost savings are on track. Product-led marketing and new products are driving positive momentum.
-
First half results met expectations, with revenue down 16% and gross margin stable year-on-year. Cost savings of £25 million were achieved, inventory and debt reduced, and the USA DTC business is expected to return to growth in H2. New product-led marketing and refinancing support future growth.